Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Select Medical Holdings (SEM) Shares Outstanding (Weighted Average) (2018 - 2026)

Select Medical Holdings (SEM) has disclosed Shares Outstanding (Weighted Average) for 9 consecutive years, with $120.7 million as the latest value for Q1 2026.

  • For Q1 2026, Shares Outstanding (Weighted Average) fell 4.39% year-over-year to $120.7 million; the TTM value through Mar 2026 reached $120.7 million, down 4.39%, while the annual FY2025 figure was $122.6 million, 1.58% down from the prior year.
  • Shares Outstanding (Weighted Average) hit $120.7 million in Q1 2026 for Select Medical Holdings, down from $122.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $129.0 million in Q1 2022 and bottomed at $120.5 million in Q3 2025.
  • Average Shares Outstanding (Weighted Average) over 5 years is $123.7 million, with a median of $123.4 million recorded in 2025.
  • Year-over-year, Shares Outstanding (Weighted Average) dropped 6.43% in 2022 and then rose 1.89% in 2025.
  • Select Medical Holdings' Shares Outstanding (Weighted Average) stood at $124.6 million in 2022, then decreased by 1.22% to $123.1 million in 2023, then grew by 1.23% to $124.6 million in 2024, then fell by 1.58% to $122.6 million in 2025, then fell by 1.62% to $120.7 million in 2026.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $120.7 million, $122.6 million, and $120.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.